• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Inspections, Compliance, Enforcement, and Criminal Investigations

  • Print
  • Share
  • E-mail

Monterey Peninsula Airport District 25-Jan-02


Public Health Service

Food and Drug Administration

1431 Harbor Bay Parkway

Alameda, CA 94502-7070

Telephone: 510-337-6700



January 25, 2002

Our Reference Number: FE13003383303

Nancy J. Soy, Board of Directors Chairperson

Monterey Peninsula Airport District

200 Fred Kane Drive, Suite 200 4165 0463 21i5

Monterey, CA 93940

Dear Ms. Soy,

On January 9, 2002, FDA Investigator Loma Jones conducted an inspection of your facility located at Monterey Peninsula Airport, Monterey, CA, which provides waste service to all airlines utilizing the Monterey Peninsula Airport. Your operations at this site are in serious violation of Interstate Conveyance Sanitation regulations which are established in Title 21, Code of Federal Regulations, Part 1250 (21 CFR 1250). Investigator Jones? observations were listed on Form FDA 483, List of Inspectional Observations, a copy of which was provided to, and discussed with, Ms. Jacqueline

Hulsey, Chief of Operations & Maintenance/Operations Manager, at the conclusion of the inspection.

Investigator Jones? observations include the following: The airport? s waste service area continues to dump aircraft sewage into a manhole, which is not a properly constructed sewage disposal facility. Water is not available for tenants to use during dumping of aircraft sewage. The deficiencies found at your facility could contribute to the spread of communicable diseases, in consequence of which your operation has been assigned a "Provisional" classification. If the deficiencies are not corrected within thirty (30) days from the receipt of this notification, your facility will be placed on "Not Approved" status. Assignment of "Not Approved" status prohibits the use of your waste disposal services for interstate conveyances until the violations have been corrected and the facility has been re-inspected by FDA.

You should notify this office within fifteen (15) working days of the receipt of this letter of the specific steps that you have taken to prevent a recurrence of the cited deficiencies.

Your response should be directed to:

Warren E. Savary, Compliance Officer

U.S. Food and Drug Administration

143 1 Harbor Bay Parkway

Alameda, CA 94502

You may wish to FAX your response to Mr. Savary at (510) 337-6707.


Dennis Linsley


San Francisco District